Home / Industry / Healthcare IT / PD-L1 Biomarker Testing Market

PD-L1 Biomarker Testing Market

PD-L1 Biomarker Testing Market Insights, Competitive Landscape, and Market Forecast 2033

Published Date: Jun 2026 | Format: | No. of Pages: 190

Industry: Healthcare IT | Author Name: Sayali

Request Sample / Information

  
$4,994.00
Buy now
Report Description Research Methodology

FAQ : PD-L1 Biomarker Testing Market

The global PD-L1 biomarker testing market is valued at US$ 840.10 Million in 2026 and is projected to reach US$ 1,468.01 Million by 2033, growing at a CAGR of 8.3%.

Market growth is driven by rising cancer incidence worldwide and the expanding use of companion diagnostic testing for immunotherapy treatment selection.

Non-Small Cell Lung Cancer (NSCLC) leads the market with a 43.6% share due to the widespread clinical requirement for PD-L1 testing before initiating immunotherapy.

North America dominates the market with a 41.3% share, supported by extensive adoption of checkpoint inhibitors, strong reimbursement systems, and a high concentration of approved companion diagnostics.

The greatest opportunity lies in the development of blood-based PD-L1 companion diagnostic assays that enable non-invasive and recurring treatment monitoring.
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services